You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Multiple Myeloma in Relapse

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

MMRR Treated With Belantamab Mafotidine on Monotherapy

Not yet recruiting
  • Multiple Myeloma
  • Belantamab mafodotin
  • (no location specified)
May 23, 2022

Selinexor, Daratumumab and Dexamethasone in Chinese Multiple

Not yet recruiting
  • Multiple Myeloma at First Relapse
    • (no location specified)
    Sep 27, 2022

    Refractory Multiple Myeloma, Relapse Multiple Myeloma, Multiple Myeloma Trial in Boston (Elranatamab)

    Not yet recruiting
    • Refractory Multiple Myeloma
    • +2 more
    • Boston, Massachusetts
    • +2 more
    Nov 17, 2023

    Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial (Venetoclax)

    Not yet recruiting
    • Multiple Myeloma in Relapse
    • Multiple Myeloma, Refractory
    • (no location specified)
    Oct 30, 2023

    Multiple Myeloma Trial in Houston (Belantamab mafodotin)

    Recruiting
    • Multiple Myeloma
    • Belantamab mafodotin
    • Houston, Texas
      M D Anderson Cancer Center
    Jan 5, 2023

    Multiple Myeloma in Relapse Trial in Shenzhen (BCMA/GPRC5D double CAR-T)

    Recruiting
    • Multiple Myeloma in Relapse
    • BCMA/GPRC5D double CAR-T
    • Shenzhen, Guangdong, China
      Shenzhen Qianhai Shekou Free Trade Zone Hospital
    Sep 28, 2023

    Multiple Myeloma, Multiple Myeloma in Relapse Trial (Belantamab mafodotin, Venetoclax)

    Not yet recruiting
    • Multiple Myeloma
    • Multiple Myeloma in Relapse
    • Belantamab mafodotin, Venetoclax
    • (no location specified)
    May 10, 2023

    Health Technology Intervention on Patient Activation in Multiple

    Not yet recruiting
    • Multiple Myeloma in Relapse
    • +3 more
      • (no location specified)
      Jan 9, 2023

      Relapse/Refractory Multiple Myeloma Trial in Hangzhou (DeepTag-GPRC5D Targeted CAR T-cells)

      Recruiting
      • Relapse/Refractory Multiple Myeloma
      • DeepTag-GPRC5D Targeted CAR T-cells
      • Hangzhou, Zhejiang, China
        The first affiliated hospital of medical college of zhejiang uni
      Oct 10, 2023

      Multiple Myeloma, Relapse Multiple Myeloma Trial in Chicago (Belantamab mafodotin, Carfilzomib, Pomalidomide)

      Not yet recruiting
      • Multiple Myeloma
      • Relapse Multiple Myeloma
      • Belantamab mafodotin
      • +3 more
      • Chicago, Illinois
        University of Chicago Medicine Comprehensive Cancer Center
      Mar 23, 2023

      Learn How Triple Class Refractory Multiple Myeloma Are Treated

      Not yet recruiting
      • Relapse Multiple Myeloma
      • Refractory Multiple Myeloma
        • (no location specified)
        Feb 15, 2023

        Multiple Myeloma in Relapse Trial in Aurora (Selinexor, Pomalidomide, Daratumumab)

        Recruiting
        • Multiple Myeloma in Relapse
        • Aurora, Colorado
          University of Colorado Hospital
        Jan 31, 2023

        Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial (Carfilzomib, Cyclophosphamide, Dexamethasone)

        Not yet recruiting
        • Multiple Myeloma in Relapse
        • Multiple Myeloma, Refractory
        • (no location specified)
        Jun 8, 2023

        Multiple Myeloma Trial in Hamburg (allogeneic HSCT)

        Completed
        • Multiple Myeloma
        • allogeneic HSCT
        • Hamburg, Germany
          University Medical Center Hamburg-Eppendorf
        Sep 1, 2022

        Multiple Myeloma, Allogeneic Stem Cell Transplantation Trial in Spain (CARTemis-1)

        Not yet recruiting
        • Multiple Myeloma
        • Allogeneic Stem Cell Transplantation
        • CARTemis-1
        • Santander, Cantabria, Spain
        • +4 more
        Aug 1, 2023

        Relapsed and/or Refractory Multiple Myeloma, Plasma Cell Leukemia in Relapse Trial in Shanghai (Biological)

        Recruiting
        • Relapsed and/or Refractory Multiple Myeloma
        • Plasma Cell Leukemia in Relapse
        • Biological
        • Shanghai, Shanghai, China
          Shanghai Tongji Hospital
        May 29, 2023

        Multiple Myeloma, Refractory, Multiple Myeloma in Relapse Trial in Cleveland (Autologous CAR-T cell therapy expressing the

        Not yet recruiting
        • Multiple Myeloma, Refractory
        • Multiple Myeloma in Relapse
        • Autologous CAR-T cell therapy expressing the BAFF-ligand.
        • Cleveland, Ohio
          University Hospitals Seidman Cancer Center
        Jan 11, 2023

        Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in Poitiers (Isatuximab, Carfilzomib, Pomalidomide)

        Active, not recruiting
        • Multiple Myeloma in Relapse
        • Multiple Myeloma, Refractory
        • Poitiers, France
          CHU Poitiers
        Jan 9, 2023

        Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial (Anti-GPRC5D CAR-T Cells Injection)

        Not yet recruiting
        • Multiple Myeloma in Relapse
        • Multiple Myeloma, Refractory
        • Anti-GPRC5D CAR-T Cells Injection
        • (no location specified)
        Feb 18, 2023

        Multiple Myeloma, Relapse, Refractory Trial in Chapel Hill, Winston-Salem, Columbus (Isatuximab, Pomalidomide, Dexamethasone)

        Not yet recruiting
        • Multiple Myeloma
        • +4 more
        • Chapel Hill, North Carolina
        • +2 more
        Jun 9, 2023

        Multiple Myeloma, Relapse Multiple Myeloma Trial in Bethesda, Madison (Descartes-25)

        Recruiting
        • Multiple Myeloma
        • Relapse Multiple Myeloma
        • Shreveport, Louisiana
        • +3 more
        Nov 4, 2022

        Multiple Myeloma in Relapse, Multiple Myeloma Progression, Multiple Myeloma Stage II Trial in London (Rivaroxaban, ASA)

        Recruiting
        • Multiple Myeloma in Relapse
        • +5 more
        • London, Ontario, Canada
          London Health Sciences Centre
        Oct 3, 2022

        Long-term KRd in Relapsed and/or Refractory Multiple Myeloma

        Not yet recruiting
        • Multiple Myeloma in Relapse
        • Multiple Myeloma, Refractory
        • (no location specified)
        Aug 8, 2022

        Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in Kunming (Anti-GPRC5D CAR-T cells infusion)

        Recruiting
        • Multiple Myeloma in Relapse
        • Multiple Myeloma, Refractory
        • Anti-GPRC5D CAR-T cells infusion
        • Kunming, Yunnan, China
        • +1 more
        Feb 21, 2023

        Multiple Myeloma Trial in Cologne (Daratumumab)

        Recruiting
        • Multiple Myeloma
        • Cologne, Germany
          University of Cologne
        Apr 4, 2022